Advanced MedTech Holdings Acquires Shenzhen Huikang Medical to Advance Shockwave Medicine and Enhance Global Healthcare Solutions

VCBeat has learned that Advanced MedTech Holdings (AMTH), the holding company of Dornier MedTech, announced its acquisition of China’s Huikang Company, further advancing the medical application of shockwave therapy to help physicians benefit a broader patient population.

AMTHHeadquartered in Singapore, it is a multinational medical technology group under Temasek Holdings. It focuses on the research and development of equipment and related services in the field of urological disease treatment.Dornier MedTechIt is a wholly-owned subsidiary of AMTH.Huikang CompanyHeadquartered in Shenzhen, the technology hub known as “China’s Silicon Valley,” the company has cultivated deep expertise for many years in China’s urology and extracorporeal shock wave therapy sectors. Huikang’s extracorporeal shock wave lithotripters consistently rank among the top in terms of market share in China. Additionally, the company provides comprehensive solutions for shock wave therapy in orthopedic conditions. Huikang’s product portfolio covers the treatment of urinary calculi, erectile dysfunction, and pain associated with joints, muscles, and soft tissues.

This acquisition will expand AMTH’s product portfolio in the Chinese market and enhance its customer service capabilities by integrating Huikang’s marketing network, local R&D, manufacturing capabilities, and comprehensive supply chain system. Meanwhile, it will bolster AMTH’s product development in orthopedics, rehabilitation and pain management, and andrology, thereby expanding the multidisciplinary applications of medical shockwave therapy. The acquisition will also establish a new platform for AMTH aligned with the localization strategy for medical devices in China, enabling better service to this high-potential, rapidly growing healthcare market. It is reported that the acquisition is expected to be completed by the end of 2022.

AMTH and Dornier Teams Conduct Extensive Marketing Activities

Huikang Company, established in 1996, is dedicated to the research, development, and manufacturing of high-tech medical equipment in the field of urology, with remarkable achievements particularly in the R&D, manufacturing, and sales of extracorporeal shock wave lithotripsy (ESWL) devices. Its product portfolio includes the ESWL series, extracorporeal shock wave orthopedic therapy instruments and pain management rehabilitation series (ESWT), urological examination and treatment tables (UROT), and stone expulsion beds. The company’s products are sold throughout China and exported to more than 40 countries and regions worldwide, with a global cumulative installation base of over 6,000 ESWL machines.

Selected Products from Huikang

Dornier MedTech, a wholly-owned subsidiary of AMTH, is a long-established German medical technology enterprise and the pioneer of extracorporeal shock wave lithotripsy (ESWL) equipment and technology. As early as 1980, the world’s first extracorporeal shock wave lithotripter—the Dornier HM1—was launched in Munich, Germany, spearheading a transformative shift toward non-surgical management of urolithiasis. Leveraging its robust German R&D capabilities, Dornier has dedicated over four decades to the field of extracorporeal shock wave medicine, continuously introducing innovative, high-value-added products. From the inaugural Dornier HM1 lithotripter through dozens of generations of model upgrades, to the current integrated Dornier Delta II Pro lithotripsy system, the modular Sigma Pro lithotripter, and the Aries series of intelligent zoom-focus shock wave therapy devices for rehabilitation, Dornier provides clinicians with more convenient, efficient, and safe extracorporeal shock wave therapy solutions, while vigorously promoting the standardized development of ESWL technology.

Selected Products from Dornier MedTech

Through this acquisition, Huikang has become one of AMTH’s global R&D and manufacturing bases. Dornier’s German engineering expertise, product portfolio, and business system seamlessly integrate with Huikang’s localized innovation capabilities, creating a powerful synergy through complementary strengths. Post-acquisition, AMTH will provide comprehensive product and service solutions for patients and physicians, while establishing a high-potential R&D platform to advance the global development of urology. By deeply integrating localized R&D and manufacturing capabilities, AMTH will not only meet the demands of the Chinese healthcare market but also deliver high-quality medical urological equipment to customers worldwide.

Mr. Abel Ang, CEO of AMTH Group“He stated, ‘China, with its super-sized market, is the focal point of our rapid development and strategic layout. We have been continuously exploring ways to better serve the local Chinese market. Shenzhen Huikang Medical Apparatus Co., Ltd.’s substantial foundation in R&D, manufacturing, supply chain, and equipment installation will accelerate the integration of AMTH Group’s urology platform. The newly merged product portfolio will enable us to better serve global customers seeking value-driven, high-quality solutions in the fields of urology, orthopedics, and rehabilitation.’”

Mr. Chen Ming, Founder of Huikang Companystated: “We are delighted to join the AMTH Group. By integrating Huikang’s strengths in innovative technology, R&D, and marketing, we will more efficiently expand our medical solutions to healthcare institutions and professionals worldwide.”

Advanced MedTech Holdings is a multinational medical technology enterprise, with its core business focused on urology equipment and contract manufacturing services. The Group serves millions of patients and physicians in over 100 countries worldwide. Advanced MedTech Holdings makes strategic investments in various disruptive medical technology companies to enhance the healthcare solutions it provides to global customers. Advanced MedTech Holdings is a wholly-owned subsidiary of Temasek Holdings.

Dornier MedTech is a multinational medical device company headquartered in Munich, Germany. As a wholly-owned subsidiary of Advanced MedTech Holdings, it is the pioneer of extracorporeal shock wave lithotripsy (ESWL) equipment and technology. Driven by entrepreneurial spirit and an unwavering pursuit of excellence, Dornier is committed to continuous innovation in urology, developing high-quality urological and shock wave therapy devices available on today’s market. Dornier remains dedicated to serving its extensive customer base and improving outcomes for patients worldwide.

Shenzhen Huikang Medical Apparatus Co., Ltd., established in 1996, is dedicated to the research, development, and manufacturing of extracorporeal shockwave medical devices. Its product portfolio includes extracorporeal shockwave lithotripsy (ESWL) systems for urinary stones; extracorporeal shockwave therapy (ESWT) devices for orthopedics, rehabilitation, and pain management; treatments for erectile dysfunction; as well as diagnostic and therapeutic tables and stone expulsion beds for urological examinations and surgeries. The company is recognized as a National High-Tech Enterprise, hosts a Shenzhen Key Engineering Laboratory, serves as the Guangdong Provincial Engineering Technology Research Center for Medical Shockwave Therapy Equipment, and is designated as a Guangdong Provincial “Specialized, Refined, Differential, and Innovative” Enterprise.